Objective: The effect of diabetes type and insulin dependence on short-and long-term outcomes after lower extremity revascularization for chronic limb-threatening ischemia (CLTI) warrants additional study and more targeted focus. We sought to address this paucity of information by evaluating outcomes in insulin-dependent and noninsulin-dependent patients after any first-time revascularization.
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Questions Society for Vascular Surgery Phone: 800-258-7188; education@vascularsociety.org Results: Of 2869 infrainguinal revascularizations from 2005 to 2014, 1294 limbs (646 BPG, 648 PTA/S) fit our criteria. Overall, our analysis included 703 IDDM, 262 NIDDM, and 329 NDM limbs. IDDM patients, compared with NIDDM and NDM patients, were younger (69 vs 73 vs 77 years; P < .001) and more often presented with tissue loss (89% vs 77% vs 67%; P < .001), coronary artery disease (57% vs 48% vs 43%; P < .001), and end-stage renal disease (26% vs 13% vs 12%; P < .001). Perioperative complications, including mortality (3% vs 2% vs 5%; P ¼ .07), did not differ between groups; however, complete wound healing at 6-month follow-up was significantly worse among IDDM patients (41% vs 49% vs 61%; P < .001). IDDM patients had significantly higher 3-year major amputation rates (23% vs 11% vs 8%; P < .001). Multivariable analyses illustrated that compared with NDM, IDDM was associated with significantly higher risk of both major amputation and RAS events after any first-time intervention (hazard ratio, 2.0 [95% confidence interval, 1.1-4.1] and 1.4 [1.1-1.8], respectively). Similar associations between IDDM and both major amputation and RAS events were found in patients undergoing a PTA/S-first intervention (4.1 [1.3-12.6 ] and 1.5 [1.1-2.2], respectively), whereas IDDM in BPG-first patients was associated with only incomplete wound healing (2.0 [1.4-4.5]). Last, compared with NDM, NIDDM was associated with lower late mortality (0.7 [0.5-0.9]).
Conclusions: Compared with NDM, IDDM is associated with similar perioperative and long-term mortality but a higher risk of incomplete wound healing, major amputation, and future RAS events, especially after a PTA/S-first approach. NIDDM, on the other hand, is associated with lower long-term mortality and few adverse limb events. Overall, these data demonstrate both the importance of distinguishing between diabetes types and the potential long-term benefit of a BPG-first strategy in appropriately selected IDDM patients with CLTI. (J Vasc Surg 2018;67:1159-69.)
Despite advances in the management of diabetes, the profound effect of the estimated growth is still likely to yield a tremendous escalation in end-stage peripheral artery disease (PAD).
1 Chronic limb-threatening ischemia (CLTI), broadly defined as the most advanced stages of PAD and demarcated by ischemic rest pain, nonhealing ulcer, or gangrene, is significantly more likely in diabetic patients and is often a debilitating condition. 2 Ultimately, the diagnosis of PAD in patients with diabetes is often delayed because of the presence of neuropathy, as PAD-related symptoms go unnoticed until more severe CLTI symptoms develop. 3 Given the prevalence and severity of such events, nonoperative wound management and care may not be sufficient to avoid limb loss. Although open surgical bypass grafting (BPG) has been shown to have excellent results in patients with diabetes and PAD, contemporary management of CLTI has gradually favored the use of minimally invasive techniques that offer lower periprocedural morbidity and mortality, reduced costs, faster procedural times, and shortened hospital stay. 4 Several studies have compared the utility of both BPG and percutaneous transluminal angioplasty with or without stenting (PTA/S) in varying degrees of lower extremity limb ischemia and in patients with and without diabetes; however, in the current endovascular era, few studies have evaluated the degree to which these subsets of patients fare in regard to procedure type. [5] [6] [7] [8] [9] [10] [11] [12] [13] In this study, we sought to describe our institution's long-term experience with BPG-first and PTA/S-first repair in insulin-dependent, noninsulin-dependent, and nondiabetic patients.
METHODS
Subjects and settings. We performed a retrospective review of all patients with CLTI undergoing a first-time lower extremity intervention at Beth Israel Deaconess Medical Center. Medical records of all BPG and PTA/S interventions from January 2005 to October 2014 were individually reviewed. Patients were categorized as having insulin-dependent diabetes (IDDM), noninsulindependent diabetes (NIDDM), or no diabetes (NDM). IDDM was defined as preoperative or at-home reliance on insulin administration to control diabetes at baseline. Patients with diabetes who were not prescribed insulin were categorized as having NIDDM. Importantly, for the purposes of this study, insulin dependence is not considered tantamount to type 1 diabetes, as it describes the patient-level pattern of insulin use at the time of revascularization. Patients who received previous interventions on the ipsilateral limb (whether at Beth Israel Deaconess Medical Center or at an outside institution) or interventions solely at or proximal to the iliac arteries were excluded. Patients undergoing a concomitant procedure, including endarterectomy, profundaplasty, thrombectomy, atherectomy, and patch, were included and adjusted for in our multivariable analyses. The interval for typical patient follow-up was every 3 to 4 months for 2 years and every 6 months afterward; the modality of follow-up was arterial duplex ultrasound imaging and ankle-brachial indices with forefoot pulse volume recordings or toe pressures.
Our analysis included patients whose disease severity was distinctly classifiable as CLTI and who underwent either first-time BPG or first-time PTA/S. Indications for intervention included tissue loss (ie, gangrene and ulcer) and rest pain. Patients presenting with more than one indication were assigned hierarchically, with gangrene constituting the most severe indication, followed by ulcer, and then rest pain. Femoropopliteal lesion anatomy and severity were defined according to the modified TransAtlantic Inter-Society Consensus II (TASC II) classification. As there was no updated TASC class for tibial lesions included in the modified TASC II classification, tibial lesion information was defined by TASC I. 14, 15 Measurements and outcome variables. Primary outcomes included perioperative complications, wound healing, major amputation, RAS events (a composite variable denoted by reintervention, major amputation, or stenosis), major adverse limb events (MALE; a composite variable denoted by any major amputation or any major reintervention, defined as creation of a new bypass graft, a jump graft revision, surgical thrombectomy with or without surgical patch angioplasty, and thrombectomy of an occluded graft or arterial segment using pharmacologic or mechanical thrombolysis), and mortality. 16 Demographics, comorbidities, Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) information, restenosis, and reintervention were also recorded. 17 Perioperative complications included hematoma, acute myocardial infarction, and death. Cardiac enzymes and electrocardiograms were not routinely obtained after revascularization. If patients developed chest pain, dyspnea, hemodynamic instability, or other concerning signs or symptoms, an electrocardiogram was obtained with cardiac enzymes (if the patient had electrocardiographic changes or strong history of coronary disease). The criterion for restenosis was at least 75% stenosis by angiographic measurement or a >3.5-fold increase in peak systolic velocity by duplex ultrasound.
Reinterventions included any ipsilateral surgical or endovascular revision and were most commonly performed for symptomatic graft restenosis or threatened asymptomatic grafts (peak systolic velocity ratio >3.5 to 4 or low graft velocities <30 cm/s). Ordinarily, patients did not undergo reinterventions for an asymptomatic restenosis after PTA alone; however, attending physicians were more likely to reintervene with PTA/S for an asymptomatic in-stent restenosis if the peak systolic velocity ratio was >3.5 to 4. Type of reintervention strategy was surgeon dependent and varied over time with the acquisition of endovascular skills. In general, PTA/S-first strategies were performed according to the clinical judgment of the attending physician at the time of angiography. After BPG, patients were prescribed aspirin and a statin and were not prescribed clopidogrel. Anticoagulation and cilostazol use were dependent on the attending physician and varied with operative findings. In addition, patients undergoing PTA/S below the inguinal ligament received dual antiplatelet therapy for 30 days, followed by aspirin indefinitely. Routine statin use was introduced over time. Technical success after PTA/S was defined as <30% residual stenosis and no flow-limiting dissection; technical success after BPG included a patent bypass graft at completion, which was defined as one without significant defect in the vein on angioscopy and continuous-wave Doppler interrogation. Both preoperative vein mapping and angioscopy were used in all BPG cases, and all patients undergoing any revascularization received general anesthesia. 18 Statistical analyses. Contingent on the outcome of interest, analyses were performed on either a per-limb basis (ie, wound healing, stenosis, reintervention, amputation, RAS events, MALE) or a per-patient basis (ie, mortality); on per-patient outcomes, the initial limb was censored at the procedure date of the contralateral limb.
Pearson c 2 and Fisher exact tests were used for categorical variable comparison. Continuous variables were compared using Student t-test or Mann-Whitney U test. Rates were compared across strata (IDDM, NIDDM, and NDM) using c 2 analysis. Treatment outcomes during the course of follow-up were analyzed using Kaplan-Meier methodology, and unadjusted time-to-failure curves were compared with the log-rank test. Covariates were selected using purposeful selection, incorporating backward selection after a univariate screen (P < .10) as well as including relevant patient factors previously identified. 19 Multivariable Cox regression models were constructed to assess independent associations between diabetes type and time-dependent outcomes. Statistical significance was defined as P < .05. All statistical tests were done using Stata 13 (StataCorp LP, College Station, Tex). The Beth Israel Deaconess Medical Center Institutional Review Board approved this study and waived the need for patient consent.
RESULTS
Baseline characteristics. Of the 2869 total lower extremity revascularizations performed between January 2005 and October 2014, 667 were performed on patients with non-CLTI symptoms, 475 were reinterventions, and 433 were performed on patients who had undergone interventions before 2005; ultimately, 1294 limbs in 1160 patients met our inclusion criteria (ie, a first-time lower extremity intervention for CLTI with reliable insulin information), 646 undergoing primary BPG and 648 undergoing primary PTA/S. As Fig 1, A illustrates Recommendation: This study suggests that increased attention should be paid to insulin dependency in diabetics with chronic limb-threatening ischemia as it is associated with poorer outcomes after first-time revascularization compared with noninsulin-dependent diabetics or nondiabetics. Overall, 703 IDDM, 262 NIDDM, and 329 NDM limbs were included in our analysis. IDDM patients, compared with NIDDM and NDM patients, respectively, were younger (69 vs 73 vs 77 years; P < .001) and more often presented with tissue loss (89% vs 78% vs 67%; P < .001), coronary artery disease (57% vs 48% vs 43%; P < .001), and end-stage renal disease (26% vs 13% vs 12%; P < .001; Table I ). Conversely, NDM patients more commonly suffered from chronic obstructive pulmonary disease (10% vs 9% vs 19%; P < .001) and more frequently smoked (57% vs 58% vs 69%; P ¼ .001). Groups did not differ in male sex (62% vs 57% vs 56%; P ¼ .13) or in rates of congestive heart failure (34% vs 28% vs 28%; P ¼ .10). There was no difference in the proportion of patients undergoing primary BPG by diabetes type (49% vs 51% vs 52%; P ¼ .58). The prevalence of preoperative femoropopliteal TASC D lesions was lowest in IDDM patients (17% vs 19% vs 31%; P < .001), although this difference was not seen when directly comparing IDDM to NIDDM (P ¼ .46). There was no difference in tibial TASC D lesions (32% vs 29% vs 32%; P ¼ .69). Finally, WIfI clinical stage 4 was most prevalent among IDDM patients (52% vs 43% vs 31%; P < .02), potentially driven by the high WIfI wound component among these patients (1.6 vs 1.4 vs 1.2; P < .01).
Of the 646 BPG-first procedures, the femoral artery was the most common inflow artery (74% of all procedures), although significantly less so among IDDM patients (68% vs 74% vs 84%; P ¼ .001). In directly comparing IDDM with NDM, the outflow artery among IDDM patients was less commonly the popliteal artery (29% vs 40%; P ¼ .01) and more commonly the dorsalis pedis/pedal arteries (29% vs 16%; P < .01; Table II ). Procedural details were not significantly different between IDDM and NIDDM patients or between NIDDM and NDM patients. Single-segment great saphenous vein conduits were used in more than three-quarters of procedures performed in each group (76% vs 80% vs 78%; P ¼ .56); nonreversed great saphenous vein was the most common conduit (40% vs 41% vs 39%; P ¼ .88). Composite vein conduit use (6% vs 5% vs 8%; P ¼ .49) and synthetic conduit use (12% vs 12% vs 12%; P ¼ .98) did not differ between diabetes type.
Finally, of the 648 PTA/S-first procedures, IDDM patients were less likely to undergo a superficial femoral artery angioplasty (57% vs 67% vs 75%; P < .001) and were more likely to undergo an anterior tibial angioplasty (31% vs 11% vs 16%; P < .001; Table III) . Furthermore, there were no differences in multilevel interventions (42% vs 42% vs 49%; P ¼ .34); however, femoropopliteal stenting was significantly less common among IDDM patients (26% vs 31% vs 42%; P ¼ .001), a significant difference that was most likely driven by the difference between IDDM patients and NDM patients (P < .001). NIDDM patients, compared solely with NDM patients, were significantly less likely to undergo infrapopliteal stenting (3% vs 9%; P ¼ .045).
The median follow-up for IDDM, NIDDM, and NDM patients was 1.5 years (range, <1-10 years), 1.6 years (<1-10 years), and 1.3 years (<1-10 years), respectively.
Perioperative outcomes. After any lower extremity revascularization for CLTI, IDDM patients exhibited a significantly longer total hospital length of stay (9.6 vs 8.9 vs 8.0 days; P < .01), most likely driven by the length of stay difference between IDDM and NDM patients (P < .001; Table IV ). Further univariate analysis suggested that both perioperative mortality (3.0 vs 1.5 vs 4.9; P ¼ .07) and perioperative complications (15% vs 12% vs 15%; P ¼ .60) were similar between groups. Among BPG-first patients, perioperative surgical site infections did not differ (11% vs 10% vs 8%; P ¼ .52). Regardless of procedure type, after adjusting for baseline characteristics, multivariable analysis found diabetes type not to be associated with perioperative death or complications.
Long-term outcomes. Unadjusted Kaplan-Meier analysis demonstrated that complete wound healing at 6-month follow-up was significantly worse among IDDM patients (41% vs 49% vs 61%; P < .001). Further unadjusted Kaplan-Meier analyses illustrated no significant difference in 3-year rates of restenosis (50% vs 46% vs 38%; P ¼ .36) and reintervention (36% vs 37% vs 31%; P ¼ .63) but did demonstrate significant differences in 3-year rates of major amputation (23% vs 12% vs 8%; P < .001; Fig 2) , RAS events (65% vs 55% vs 53%; P ¼ .04; Fig 3) , MALE (34% vs 26% vs 23%; P < .01; Fig 4) , and death (44% vs 35% vs 49%; P < .01; Fig 5) . After adjustment, among all procedure types, diabetes type was not shown to independently affect restenosis or reintervention. Conversely, among all revascularization 
DISCUSSION
Our data illustrate that in patients undergoing first-time lower extremity revascularization for CLTI, those suffering from IDDM present at an earlier age and with more severe disease. Regardless of revascularization strategy, there are no differences in perioperative complications, Fig 3. Unadjusted effect of diabetes type on long-term freedom from reintervention, amputation, or stenosis (RAS) among patients undergoing any lower extremity revascularization for chronic limb-threatening ischemia (CLTI). IDDM, Insulin-dependent diabetes; NIDDM, noninsulindependent diabetes; NDM, no diabetes; S.E., standard error. restenosis, or reintervention; however, IDDM was associated with longer preoperative and total hospital lengths of stay as well as with a heightened risk of incomplete wound healing, major amputation, RAS events, and MALEs. Conversely, NIDDM patientsdseemingly with the least disease burden of the three groupsdwere shown to have lower long-term mortality (compared with NDM), even after adjusting for the discrepancy in comorbidity burden. More specifically, compared with NDM patients, IDDM patients undergoing a PTA/S-first strategy were shown to have a heightened risk of incomplete wound healing, RAS events, and major amputation. Conversely, IDDM patients undergoing a BPG-first intervention were shown to be associated only with poorer wound healing, suggesting that the oft-referenced adverse outcomes in IDDM patients may be most mitigated after a BPG-first strategy.
Prior studies have illustrated that the impact of diabetes on perioperative outcomes remains controversial, with several studies demonstrating higher risk of perioperative morbidity and mortality among patients with diabetes, whereas others report no added risk in this population of patients. [20] [21] [22] [23] major amputation or future target extremity revascularization, was significantly better in nondiabetic patients (hazard ratio, 0.48) and that in both diabetic and nondiabetic patients, this success was not influenced by mode of initial revascularization. Furthermore, diabetes was not shown to be significantly associated with higher 1-year mortality (P ¼ .064). Ultimately, diabetic patients within this cohort were shown to improve to the same degree as nondiabetic patients, but only through multiple revascularization procedures and by means of close follow-up and timely repetition of target extremity revascularization. Overall, our study both differs from and corroborates previous literature. Curiously, NIDDM patients within our study were shown to have lower long-term mortality, which is a novel finding compared with prior works. In general, we believe that this outcome may be less reflective of the health of NIDDM patients and more reflective of the severity of disease among and between both IDDM and NDM patients, as NIDDM patients were less likely to have tissue loss, coronary artery disease, and congestive heart failure (compared with IDDM patients) and had decreased proportions of chronic obstructive pulmonary disease, smoking history, and femoropopliteal TASC D lesions (compared with NDM patients).
Although a surprising finding, the lower mortality among NIDDM patients may further reveal betterdor simplerd long-term medical management or the potential additional increase in cardiac risk within the IDDM and NDM patients that is not presently captured within this analysis. Importantly, in combining IDDM and NIDDM groups, our study substantiates the insignificant differences in long-term mortality that several previous studies have demonstrated, further highlighting the importance of evaluating the distinction between IDDM and NIDDM within CLTI patients. 22, 23, 25, 27 There are important limitations to this study. First, it was a retrospective, single-center review in which patients were allocated to treatment on the basis of the surgeon's preference, which changed over time. As our data represent the experience of one group of surgeons at a single institution, the potential for selection and information bias exists, and our results are subject to the influence of specific referral patterns, surgeon experience, and patient selection preferences. Second, these data include only revascularization attempts and do not reflect outcomes for those patients treated with primary amputation or medical management as a contrast. Fortunately, several previously published studies have illustrated Additionally adjusted for age and gender; indication for intervention; symptom status, ambulatory status, and living status; race; renal disease, coronary artery disease, hypertension, hyperlipidemia, history of myocardial infarction, and congestive heart failure; TransAtlantic Inter-Society Consensus (TASC) classification; smoking history and chronic obstructive pulmonary disease; Wound, Ischemia, and foot Infection (WIfI) mean score; year of procedure; and procedure type (for any intervention group only).
both the poor outcomes after medical management and the importance of revascularization in diabetic patients with CLTI. 21, 22, [27] [28] [29] [30] Third, information about onset of diabetes and diabetes symptoms was difficult to accurately capture within this study, which may be important to consider in regard to certain differences illustrated between diabetes types, perhaps most importantly noticed in the patients' age. Last, because supplementary measures of diabetes disease severity were not readily accessible for this study, including the patients' hemoglobin A 1c level, a replacement for disease severity was baseline insulin reliance and administration, which could increase potential for confounding factors. Ultimately, however, our data include one of the largest reported analyses of the effect of diabetes type on the initial revascularization for CLTI.
CONCLUSIONS
Our data suggest that insulin dependence in patients undergoing any first-time revascularization for CLTI may have a disease severity-dependent limb effect on a variety of long-term outcomes. NIDDM is not associated with these long-term events and, compared with NDM patients, is actually associated with lower long-term mortality. Overall, these data demonstrate the importance of distinguishing between diabetes type, as insulin-dependent, noninsulin-dependent, and nondiabetic patients all present with differing degrees of disease and comorbid conditions that harbor varying degrees of limb-based and patient-based risk. Finally, although insulin dependence is associated with the greatest risk of adverse outcomes, these data suggest that these adversities may be most mitigated in those IDDM patients who are appropriately selected and anatomically suitable for a bypass. 
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